JP Morgan 2023 – Alexandre LeVert
Editor-in-chief Jonah Comstock caught up with Alexandre LeVert, chairman, CEO, and co-founder of Osivax, on the sidelines of JP Morgan in San Francisco at the beginning of January of this year.
Osivax is focused on developing vaccines against respiratory viruses with a high rate of mutation. It’s a field that’s become especially important and high-profile in the last few years for obvious reasons, but LeVert’s vision is bigger than just a better flu shot or COVID jab – his company ultimately wants to create a single shot that could protect against flu, COVID, RSV, and even rhinovirus.
LeVert talks about the difficulty in striking a balance between offering their expertise during the COVID crisis and working away on their current priority - influenza - and discusses how their T-cell-based technology can create a vaccine that protects against a wide range of strains and mutations, including those yet undiscovered.
Watch the full interview below and stay tuned for more from JP Morgan 2023.